A new study published in the European Journal of Medical Research revealed that dapagliflozin, a sodium-glucose ...

The study tested the effects of balcinrenone/dapagliflozin, a drug combination, both in fed and fasted states, and with the addition of quinidine, a P-gp inhibitor. The purpose is to understand how ...

At the recent SEC meeting for endocrinology and metabolism, the expert panel reviewed the proposal along with the ...

The rate of all-cause mortality was 7.8% in the dapagliflozin arm and 8.9% in the control arm (HR, 0.87 [95% CI, 0.59-1.28]). Regarding safety, genital infections and hypotension were reported ...

Dapagliflozin dose was 10 mg/day, whereas the spironolactone dose varied from 25 mg every other day to 25 mg/day based on eGFR and serum potassium.

Dapagliflozin, a sodium-glucose cotransporter 2 (SGLT2) inhibitor, did not significantly reduce the risk of organ failure or death or improve recovery in patients hospitalized with COVID-19 who ...

Meeting Coverage > AACE Dapagliflozin Tied to Drop in Hepcidin Levels — Decrease may boost hematocrit and hemoglobin after SGLT-2 inhibitor therapy by Kristen Monaco, Staff Writer, MedPage Today ...

Dapagliflozin, an inhibitor of SGLT2, a target in the kidney, is being investigated to evaluate its safety and efficacy in improving glycemic control in adults with type 2 diabetes, as an adjunct ...

Dapagliflozin (Farxiga) is the first SGLT2 inhibitor approved to treat patients with HFrEF, or a left ventricular ejection fraction less than 40%, according to a press release from the company.

In the DAPA-CKD trial, treatment with the SGLT2 inhibitor dapagliflozin reduced risk for worsening renal function and death due to CVD or renal disease in patients with chronic kidney disease ...